Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study
Journal of Clinical Lipidology · 2026-09 · 20 (9) · 2041-2045
DOI: 10.1016/j.jacl.2026.06.026 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Clinical Lipidology, 2026-09. Verfasst von Mohamad Mahdi Osman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44106, United States (Osman). Electronic address: osmanm4@ccf.org. Hauptthemen laut MEDLINE: Liver Cirrhosis, Fatty Acids, Dicarboxylic Acids, Cardiovascular Diseases. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Data on bempedoic acid in cirrhosis are limited. OBJECTIVE: To evaluate associations between bempedoic acid use and clinical outcomes in adults with cirrhosis. METHODS: We conducted a retrospective TriNetX cohort study comparing adults with cirrhosis receiving versus not receiving bempedoic acid. Patients with end-stage renal disease or prior liver transplantation were excluded. Propensity score matching was performed 1:1 using demographic, clinical, medication, and laboratory variables. Outcomes were mortality, hospitalization, hepatic decompensation, and major adverse cardiovascular events. RESULTS: After matching, 325 pairs were analyzed. Bempedoic acid use was associated with lower all-cause mortality (hazard ratio [HR], 0.28; 95% CI, 0.17-0.45; P < 0.001) and all-cause hospitalization (HR, 0.52; 95% CI, 0.40-0.68; P < 0.001). No significant differences were observed in hepatic decompensation (HR, 0.96; 95% CI, 0.62-1.50; P = .86) or MACE (HR, 0.84; 95% CI, 0.50-1.39; P = .49) did not differ. CONCLUSION: Bempedoic acid was associated with lower mortality and hospitalization without increased hepatic decompensation. Residual confounding and immortal time bias limit causal interpretation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH 44106, United States (Osman). Electronic address: osmanm4@ccf.org.
- Department of Gastroenterology, Weill Cornell, New York, NY 10021, United States (Massad).
- Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH 44106, United States (Sims and Chiang); Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleve…
- Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic Foundation, Cleveland, OH 44106, United States (Sims and Chiang); Cleveland Clinic Lerner College of Medicine of Case Western Reserve University…
Zitieren
APA
Osman, M. M., Massad, T., Sims, O. T., & Chiang, D. J. (2026). Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study. Journal of Clinical Lipidology, 20(9), 2041-2045. https://doi.org/10.1016/j.jacl.2026.06.026
Vancouver
Osman MM, Massad T, Sims OT, Chiang DJ. Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study. Journal of Clinical Lipidology. 2026;20(9):2041-2045. doi:10.1016/j.jacl.2026.06.026
BibTeX
@article{Osman2026,
author = {Osman, Mohamad Mahdi and Massad, Talal and Sims, Omar T and Chiang, Dian J},
title = {Mortality, cardiovascular, and hepatic decompensation outcomes of bempedoic acid in patients with cirrhosis: A multi-institutional study},
journal = {Journal of Clinical Lipidology},
year = {2026},
volume = {20},
number = {9},
pages = {2041--2045},
doi = {10.1016/j.jacl.2026.06.026}
}
EUVIMED